Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million

B Backed by Decheng Capital, Loyal Valley Capital, OrbiMed, and Other Renowned Investors SHANGHAI, April 29, 2026 /PRNewswire/ — Vivacta Biotechnology (Shanghai) Co., Ltd. (“Vivacta” or…
posteditor
posteditor
Articles: 17424

Other News